Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct;192(5):759-63.
doi: 10.1007/s00408-014-9604-7. Epub 2014 Jun 26.

EGFR mutation testing practice in advanced non-small cell lung cancer

Jair Bar  1 , Arnold Cyjon, Dov Flex, Hadas Sorotsky, Haim Biran, Julia Dudnik, Nili Peylan-Ramu, Nir Peled, Hovav Nechushtan, Maya Gips, Rivka Katsnelson, Shoshana Keren Rosenberg, Ofer Merimsky, Amir Onn, Maya Gottfried
Affiliations

EGFR mutation testing practice in advanced non-small cell lung cancer

Jair Bar et al. Lung. 2014 Oct.

Abstract

Purpose: Testing tumor samples for the presence of a mutation in the epithelial growth factor receptor (EGFR) gene is recommended for advanced non-squamous non-small cell lung cancer (NSCLC) patients. We aimed to collect data about common practice among Medical Oncologists treating lung cancer patients, regarding EGFR mutation testing in advanced NSCLC patients.

Methods: An internet-based survey was conducted among members of the Israeli Society for Clinical Oncology and Radiotherapy involved in the treatment of lung cancer patients.

Results: 24 Oncologists participated in the survey. The participants encompass the Oncologists treating most of the lung cancer patients in Israel. 79% of them use EGFR testing routinely for all advanced NSCLC patients. Opinions were split regarding the preferable biopsy site for EGFR testing material. 60% of participants recommend waiting for EGFR test results prior to initiation of first-line therapy.

Conclusions: EGFR testing is requested in Israel routinely by most treating Oncologists for all advanced NSCLC patients, regardless of histology. In most cases, systemic treatment is deferred until the results of this test are received.

PubMed Disclaimer

References

    1. Ann Oncol. 2012 Oct;23 Suppl 7:vii56-64 - PubMed
    1. Oncologist. 2012;17(7):978-85 - PubMed
    1. Cancer Discov. 2011 Jun;1(1):78-89 - PubMed
    1. Nature. 2013 May 2;497(7447):108-12 - PubMed
    1. J Clin Oncol. 2012 Sep 1;30(25):3077-83 - PubMed

MeSH terms

LinkOut - more resources